



**Universiteit
Leiden**
The Netherlands

ASO visual abstract: surgical outcome after pancreatoduodenectomy for duodenal adenocarcinoma compared with other periampullary cancers - a nationwide audit study

Bakker, J.K. de; Suurmeijer, J.A.; Toennaer, J.G.J.; Bonsing, B.A.; Busch, O.R.; Eijck, C.H. van; ... ; Dutch Pancreatic Canc Grp

Citation

Bakker, J. K. de, Suurmeijer, J. A., Toennaer, J. G. J., Bonsing, B. A., Busch, O. R., Eijck, C. H. van, ... Kazemier, G. (2022). ASO visual abstract:: surgical outcome after pancreatoduodenectomy for duodenal adenocarcinoma compared with other periampullary cancers - a nationwide audit study. *Annals Of Surgical Oncology*.
doi:10.1245/s10434-022-12779-4

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3566988>

Note: To cite this publication please use the final published version (if applicable).



ASO Visual Abstract: Surgical Outcome After Pancreatoduodenectomy for Duodenal Adenocarcinoma Compared with Other Periapillary Cancers—A Nationwide Audit Study

Jacob K. de Bakker, MD^{1,2}, J. Annelie Suurmeijer, MD^{2,3}, Jurgen G. J. Toennaer, MD^{1,2}, Bert A. Bonsing, MD, PhD⁴, Olivier R. Busch, MD, PhD^{2,3}, Casper H. van Eijck, MD, PhD⁵, Ignace H. de Hingh, MD, PhD⁶, Vincent E. de Meijer, MD, PhD⁷, I. Quintus Molenaar, MD, PhD⁸, Hjalmar C. van Santvoort, MD, PhD⁸, Martijn W. Stommel, MD, PhD⁹, Sebastiaan Festen, MD, PhD¹⁰, Erwin van der Harst, MD, PhD¹¹, Gijs Patijn, MD, PhD¹², Daan J. Lips, MD, PhD¹³, Marcel Den Dulk, MD, PhD¹⁴, Koop Bosscha, MD, PhD¹⁵, Marc G. Besselink, MD, PhD^{2,3}, Geert Kazemier, MD, PhD^{1,2} for the Dutch Pancreatic Cancer Group

¹Department of Surgery, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; ²Cancer Center Amsterdam, Amsterdam, The Netherlands; ³Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; ⁴Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; ⁵Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; ⁶Department of Surgery, Catharina Cancer Institute, Eindhoven, The Netherlands; ⁷Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ⁸Department of Surgery, Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center, Utrecht, The Netherlands; ⁹Department of Surgery, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands; ¹⁰Department of Surgery, OLVG, Amsterdam, The Netherlands; ¹¹Department of Surgery, Maasstadziekenhuis, Rotterdam, The Netherlands; ¹²Department of Surgery, Isala Clinics, Zwolle, The Netherlands; ¹³Department of Surgery, Medisch Spectrum Twente, Enschede, The Netherlands; ¹⁴Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands; ¹⁵Department of Surgery, Jeroen Bosch ziekenhuis, Den Bosch, The Netherlands

Consecutive patients after pancreatoduodenectomy for cancer between 2014 and 2019 were included from the nationwide, mandatory Dutch Pancreatic Cancer Audit. Patients were stratified by diagnosis (<https://doi.org/10.1245/s10434-022-12701-y>). Baseline, treatment

characteristics, and postoperative outcome were compared between groups. Pancreatoduodenectomy for duodenal adenocarcinoma is associated with higher rates of major complications, pancreatic fistula, re-interventions, and in-hospital mortality compared with patients undergoing pancreatoduodenectomy for other cancers. These findings should be considered in patient counseling and postoperative management.

Jacob K. de Bakker and J. Annelie Suurmeijer Share first authorship.

Marc G. Besselink and Greet Kazemier Share senior authorship.


© Society of Surgical Oncology 2022

J. K. de Bakker, MD
e-mail: j.debakker@amsterdamUMC.nl

M. G. Besselink, MD, PhD
e-mail: m.besselink@amsterdamUMC.nl

G. Kazemier, MD, PhD
e-mail: g.kazemier@amsterdamUMC.nl

Surgical Outcome After Pancreatoduodenectomy for Duodenal Adenocarcinoma Compared to Other Periapillary Cancers: A Nationwide Audit Study



FUNDING This study was funded by Deltaplan Alvleesklierkanker and Dutch Institute for Clinical Auditing. They were not involved in the study design or drafting of the manuscript.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.